Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, certolizumab pegol (Cimzia®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other disease-modifying antirheumatic drugs. |
||
|
||
Medicine details |
||
| Medicine name | certolizumab pegol (Cimzia®) | |
| Formulation | 200 mg/ml solution for injection | |
| Reference number | 1729 | |
| Indication | In combination with methotrexate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other disease-modifying antirheumatic drugs |
|
| Company | UCB Pharma Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/04/2016 | |